DNA as a target for anticancer compounds screening directly by resonance light scattering technique
Zhanguang Chen1, Yurui Peng, Maohuai Chen
1Department of Chemistry, Shantou University, Shantou, 515063, China. kqlu@stu.edu.cn
The Analyst
|August 18, 2010
Summary
A new resonance light scattering (RLS) assay directly screens DNA-targeting anticancer drugs. This method accurately reflects drug-DNA binding intensity and anticancer activity, offering a rapid and reliable screening tool.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Pharmacology
Background:
- Anticancer drugs targeting DNA can alter its structure, inhibiting replication and transcription.
- Developing efficient methods for screening these DNA-interacting anticancer agents is crucial for drug discovery.
Purpose of the Study:
- To propose and validate a novel instrument-based assay for directly screening DNA-targeted anticancer drugs.
- To utilize the resonance light scattering (RLS) technique for monitoring drug-DNA interactions.
Main Methods:
- Investigated interactions between DNA and three anticarcinogens: Adriamycin (ADM), Bleomycin A (BLMA), and Actinomycin D (ACTD).
- Employed a common spectrofluorometer to measure resonance light scattering (RLS) signals.
- Determined binding constants (K) and binding numbers (N) for each drug-DNA interaction.
Main Results:
- Established the binding sequence based on RLS: Actinomycin D (ACTD) > Adriamycin (ADM) > Bleomycin A (BLMA).
- Binding constants (K_RLS) followed ACTD > ADM > BLMA, while binding numbers (N_RLS) followed BLMA > ADM > ACTD.
- Observed a combination intensity sequence (ACTD-DNA > ADM-DNA > BLMA-DNA) consistent with known drug activities.
Conclusions:
- The RLS assay provides a direct, rapid, and reliable method for screening DNA-targeted anticancer drugs.
- This technique offers a significant advancement in applying RLS for drug discovery and evaluation.
- The assay's results correlate well with established anticancer drug activity, validating its efficacy.
